Decrease In Total Cholesterol Research Articles

Study of the protective role of ginseng aqueous extract on Lipid profile (TC), (Tg), (HDL) and (LDL) in male rabbits treated with lead acetate for 30 days

The Study involved twenty healthy adult white male rabbits (Lepus arcticus L.). the average weight (1500- 1600) Kg and aged from eight months to one year. The rabbits ware divided to four groups(G) each group contains five rabbits. G1 was treated with normal saline (1.5) ml orally as negative control group, G2 was treated with lead acetate (150) mg/kg as positive control group, G3 was treated with the aqueous extract of the Panax ginseng (400 ) mg/kg b.wt and G4 was treated with the aqueous extract of the Panax ginseng ( 400) mg/kg b.wt after 3 hours given them lead acetate (150 mg/kg b. wt/day) for peroid 30 days . study aimed to determine the protective role of Panax ginseng extract on Lipid profile like total cholesterol (TC) , triglycerides (Tg) , high-density lipoproteins (HDL) , low-density lipoproteins(LDL). The result of present study showed:- increase (P<0.05) in mean levels of high-density lipoproteins (HDL) in the (G3) and (G4) group compare with Second group (positive control G2). decrease (P<0.05) in mean levels total cholesterol (TC), triglycerides (Tg) low-density lipoproteins(LDL) in group (G3) and (G4) compare with Second group (positive control G2).

Association between polymorphisms and hypermethylation of CD36 gene in obese and obese diabetic Senegalese females

BackgroundObesity and related metabolic disorders are associated with genetic and epigenetic alterations. In this study, we have examined the association between polymorphisms and hypermethylation of the CD36 gene promoter with obesity in Senegalese females with or without type 2 diabetes mellitus to identify novel molecular markers of these pathologies (obesity and type 2 diabetes mellitus).Materials and methodsThe study was conducted in Senegal with healthy lean control, obese, and obese diabetic (age; 49.98 years ± 7.52 vs 50.50 years ± 8.76 vs 51.06 ± 5.78, and body mass index (BMI); 24.19 kg/m2 ± 2.74 vs 34.30 kg/m2 ± 4.41 vs 33.09 kg/m2 ± 4.30). We determined three genetic polymorphisms of CD36 i.e., rs1761667, rs1527483, and rs3211867 by real-time polymerase chain reaction, and methylation of CPG islands of CD36 was assessed by methylation-specific polymerase chain reaction (MS-PCR) in DNA isolated from peripheral blood of each participant. Plasma sCD36 levels and DNA methyltransferase 3a (DNMT3a) levels were determined by enzyme-linked immunosorbent assay (ELISA). According to the standard laboratory protocol, all biochemical parameters were analyzed from fasting serum or plasma.ResultsFor rs1761667, obese and obese diabetic subjects had statistically significant different parameters depending on the genotypic distribution. These were waist size for obese and HDL cholesterol for obese diabetic, they were significantly higher in subjects harboring GG genotype of rs1761667 (respectively p = 0.04 and p = 0.04).For rs3211867, obese subjects harboring the AA/AC genotype had significantly higher BMI (p = 0.02) and total cholesterol (p = 0.03) than obese subjects harboring the CC genotype. At the same time, the obese diabetic subjects harboring the AA/AC genotype had total cholesterol levels significantly higher than the obese diabetic subjects harboring the CC genotype (p = 0.03). For rs1527483, only the control subjects had statistically significant different parameters depending on the genotypic distribution. The control subjects harboring the GG genotype had a significantly higher BMI than the control subjects harboring the AA/AG genotype (p = 0.003). The CD36 gene methylation was significantly 1.36 times more frequent in obese and obese diabetic compared to lean control (RR = 1.36; p = 0.04). DNMT3a levels were higher in subjects with CD36 gene methylation than in subjects without CD36 gene methylation in each group. Obese diabetic subjects with CD36 gene methylation had significantly fewer plasmas sCD36 (p = 0.03) and more LDL-cholesterol (p = 0.01) than obese diabetic subjects without CD36 gene methylation. In the control group, an increase in sCD36 levels would be associated with a decrease in total cholesterol and triglyceride levels (coef = -7647.56 p = 0.01 and coef = -2528.50 p = 0.048, respectively) would be associated with an increase in LDL cholesterol levels. For the obese group, an increase in sCD36 levels would be associated with an increase in fasting insulin levels (coef = 490.99 p = 0.02) and a decrease in glycated hemoglobin levels (coef = -1196.26 p = 0.03). An increase in the sCD36 levels would be associated with an increase in the triglyceride levels in the obese diabetic group (coef = 9937.41 p = 0.02). The AA/AC genotype of SNP rs3211867 polymorphism was significantly associated with CD36 gene methylation in the control and obese diabetic groups (respectively p = 0.05, p = 0.002; 95% CI).ConclusionThese observations suggest that polymorphisms and epigenetic changes in CD36 gene promoters may be implicated in the onset of obesity and its related complication type 2 diabetes mellitus.

Effect of a 3-Week Multidisciplinary Body Weight Reduction Program on the Epigenetic Age Acceleration in Obese Adults.

Obesity and aging share common molecular and cellular mechanisms underlying the pathophysiology of cardiovascular diseases (CVD), which occur frequently in both conditions. DNA methylation (DNAm) age, a biomarker of the epigenetic clock, has been proposed as a more accurate predictor of biological aging than chronological age. A positive difference between an individual’s chronological age and DNAm age is referred to as epigenetic age acceleration. The objective of the present study was to evaluate the effects of a 3-week in-hospital body weight reduction program (BWRP) on the epigenetic age acceleration, as well as on other cardiometabolic outcomes, in a cohort of 72 obese adults (F/M: 43/29; (chronological) age: 51.5 ± 14.5 yrs; BMI: 46.5 ± 6.3 kg/m2). At the end of the BWRP, when considering the entire population, BMI decreased, and changes in body composition were observed. The BWRP also produced beneficial metabolic effects as demonstrated by decreases in glucose, insulin, HOMA-IR, total cholesterol, and LDL cholesterol. A post-BWRP improvement in cardiovascular function was also evident (i.e., decreases in systolic and diastolic blood pressures and heart rate). The BWRP reduced some markers of systemic inflammation, particularly C-reactive protein (CRP). Finally, vascular age (VA) and Framingham risk score (FRS) were reduced after the BWRP. When considering the entire population, DNAm age and epigenetic age acceleration did not differ after the BWRP. However, when subdividing the population into two groups based on each subject’s epigenetic age acceleration (i.e., ≤0 yrs or >0 yrs), the BWRP reduced the epigenetic age acceleration only in obese subjects with a value > 0 yrs (thus biologically older than expected). Among all the single demographic, lifestyle, biochemical, and clinical characteristics investigated, only some markers of systemic inflammation, such as CRP, were associated with the epigenetic age acceleration. Moreover, chronological age was correlated with DNAm age and VA; finally, there was a correlation between DNAm age and VA. In conclusion, a 3-week BWRP is capable of reducing the epigenetic age acceleration in obese adults, being the BWRP-induced rejuvenation evident in subjects with an epigenetic age acceleration > 0 yrs. Based on the BWRP-induced decrease in CRP levels, chronic systemic inflammation seems to play a role in mediating obesity-related epigenetic remodeling and biological aging. Thus, due to the strong association of CVD risk with the epigenetic clock and morbidity/mortality, any effort should be made to reduce the low-grade chronic inflammatory state in obesity.

Omega-3 supplementation reduces oxidative stress and inflammation in the gut of obese rats

Obesity is a complex metabolic disease that does not have an effective treatment. It has been demonstrated that omega-3 fatty acids are beneficial to metabolism, but little is known about their effects in the gut. This study evaluated the effects of omega-3 supplementation in metabolic and intestinal changes caused by obesity. Obesity was induced by a high fat diet (HFD) for 20weeks in 40 rats. At 16th week, the animals were divided into 4 groups: standard diet (SD); SD+omega-3; HFD; and HFD+omega-3. Omega-3 groups were supplemented with omega-3 (1g/Kg) daily, for 4weeks. Food intake, biochemical parameters in the plasma, and markers of oxidative stress and inflammation in the gut were evaluated. HFD+omega-3 group had a decrease in total cholesterol, triglycerides and LDL compared to the HFD group. In the gut, omega-3 supplementation reduced reactive oxygen species production, lipoperoxidation, superoxide dismutase and catalase activity, NFκB activation and TNFα production. These results demonstrate that omega-3 supplementation plays a beneficial role in metabolic parameters and is able to decrease oxidative stress and intestinal inflammation in obese rats. Thus, omega-3 supplementation could be a useful tool in the treatment of obesity.

Determination of factors associated with serum cholesterol response to dairy fat consumption in overweight adults: Secondary analysis from an RCT.

Elevated intakes of saturated fatty acids (SFA) can adversely affect serum cholesterol levels. Dairy fat contains ~60% SFA, prompting healthy eating guidelines to recommend low-fat dairy. Physiological, and environmental factors influence inter-individual variance in response to food consumption. Evidence exploring the dairy matrix has differing effects of dairy fat consumption on serum cholesterol levels when consumed in the form of cheese. The extent of this variability and determinants of response to dairy fat are currently unknown. The objective of this study was to determine factors associated with lipid metabolism response to a dairy fat intervention, with a focus on serum cholesterol. A 6-week randomized parallel intervention trial was carried out in healthy volunteers (≥50 years, BMI ≥25 kg/m2). Participants (n = 104) consumed ~40 g dairy fat daily in addition to their usual diet, in 1 of 3 forms: butter, cheese, or reduced-fat cheese and butter. For this analysis, “response” was based on the percentage (%) change in serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) from pre- to post-intervention. Participants were divided into tertiles for each lipid response. The upper and lower tertiles were used to categorize participants as “responders” and “non-responders.” For TC and LDL-c, response was classified as a decrease, whereas “response” was defined as an increase for HDL-c. Clinical response was also considered, by calculating pre- and post-intervention prevalence of those meeting target levels of cholesterol recommendations. Participants demonstrating the largest % decrease (Tertile 1; “responders”) in TC had significantly higher levels of TC and HDL-c, at baseline, and lower levels of triglycerides (TAGs) compared to those in tertile 3 (i.e., TC non-responders). Those with the largest % decrease in LDL-c (Tertile 1: LDL-c responders) had higher baseline levels of LDL-c and lower levels of TAGs. Multiple regression analysis revealed that the % change in TC and LDL-c was associated with baseline TC, TAG, body weight and high-sensitivity C-reactive protein (hsCRP; P < 0.05). Previous work has demonstrated the dairy food matrix affects lipid response to dairy consumption. This study suggests that phenotypic differences may also influence response to dairy fat in overweight individuals.

Anti-diabetic and Lipidemic Effect of Muskmelon Fruits and Seeds on Streptozocin Induced Diabetic Rat

Background: The increasing prevalence of diabetes mellitus Worldwide and its complex nature of predisposing one to different ailments like obesity, eye defect, cardiovascular diseases etc. calls for alternative measures in the management of the disease. Muskmelon (Cucumis melo L.) is an underutilized food with a lot of nutritional and medical potential which are used traditionally in the management of different ailments like diabetes mellitus.&#x0D; Objective: The aim of this study was to evaluate the anti-diabetes and anti-lipidemic effects of muskmelon fruits and seeds in streptozotocin induced-diabetic rats.&#x0D; Methods: Diabetes was induced using intravenous Streptozotocin at a dose of 42 mg/kg of body weight into the tail veins to groups 2-5. Twenty-five male albino rats were divided into 5 groups, group 1 normal control, group 2- diabetic control, group 3- Glucophage treatment, group 4-500mg/kg BW muskmelon fruits extract, and group 5- 500mg/kg bw muskmelon seeds extract and were treated for 2 weeks. Fasting blood glucose, body weight, triglyceride, LDL, HDL and total cholesterol were evaluated.&#x0D; Results: The result shows that the extract caused a significant increase in the body weight, HDL-cholesterol, and a significant decrease in triglyceride, LDL-cholesterol, total cholesterol, and fasting blood glucose. Although the extract performed well there is a significant difference between the group that took Glucophage and the groups that ate muskmelon fruits and seed extract p&lt;0.05&#x0D; Conclusion: The result proved the anti-diabetic and anti-lipidemic effect of muskmelon fruits and seeds which could be added to the pool of other food used in the management of diabetes mellitus which will lead to diet diversification.

Association of lipid profile with severity of hepatitis B virus related chronic liver disease in adult

Background: Chronic liver disease (CLD) is a major health problem and contributes to a common cause of hepatocellular carcinoma, disability and death worldwide. Hepatitis B virus (HBV) is the leading cause of CLD in our country. Abnormal lipid profile is expected in those with severe liver dysfunction.&#x0D; Objective: The objective of the study was to determine the alteration of lipid profile (total cholesterol, triglyceride, LDL-C and HDL-C) in HBV positive adult CLD patients and to correlate with severity of liver damage.&#x0D; Methods: This case control study was conducted for one year between January 2018 to December 2018. One hundred and three patients, &gt;18 years old, admitted with HBV positive CLD in Dhaka Medical College Hospital were recorded as case and 103 age and sex matched, healthy population, were recorded as control. A standard case record form including demographics, histories, clinical examinations and different investigations were completed for each group. Then lipid profile values of cases were compared to controls and different Child-Pugh and MELD scores, were used to see severity of liver damage in CLD patients.&#x0D; Results: In patients with HBV positive adult CLD, there were a significant decrease in serum total cholesterol. LDL-C and HDL-C levels compared to the control group (mean 131.4 vs 179.3, 72.5 vs 109.6, and 31.0 vs 40.4 mg/dl, respectively; p&lt;0.001). Comparison of lipid profile with pathologic progression of CLD revealed that these values were diminished gradually with progression of liver damage. Overall triglyceride level was decreased marginally in cases when compared to controls (mean 139.2 vs 146.6 and p=0.047) and this reduction was observed in only advanced stage.&#x0D; Conclusion: Serum total cholesterol, LDL-C and HDL-C level in HBV positive CLD patients were low and diminished gradually with severity of liver damage. Triglyceride level was marginally significant and diminished in advanced CLD.&#x0D; Bang Med J Khulna 2021; 54 : 08-12

Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels.

Obesity is associated with an accelerated aging process, which prevents healthy aging. Both obesity and aging were manifested in the peroxisome proliferator-activated receptor-γ coactivator α (PGC-1α) level. These studies fulfill the scientific gap in assembled pharmacological activity assay of Caulerpa racemosa done in a previous preclinical trial. Six major compounds from sea grape (C. racemosa) extract were evaluated using an in silico approach against human pancreatic lipase, a-glucosidase, and a-amylase to predict prospective anti-obesity candidates. The lipase inhibitory activity of the extract reached 90.30 ± 0.40%, 1.75% lower than orlistat. The a-amylase inhibitory assay of the extract was 84.07 ± 5.28%, while the inhibitory activity against a-glucosidase was 81.67 ± 1.54%; both were lower than acarbose. We observe the effect of C. racemosa extract as anti-obesity with anti-aging by evaluating the obesity parameters in the human body for a 4-week period. There was a significant decrease in blood glucose, total cholesterol, low-density lipoprotein (LDL), triglycerides (TG), waist circumference, waist-hip ratio, and body weight (p < 0.05); PGC-1α and high-density lipoprotein (HDL) increased significantly (p = 0.000), in Group B when compared with Group A. Our study revealed that sea grape extract is a potent anti-obesity with an anti-aging reagent that does not produce any significant adverse effects.

Evaluation of serum lipid profile in breast cancer patients: a case control study

Objective: This study was conducted to investigate the relationship between serum lipid profile and breast cancer disease.Patients and methods: One hundred breast cancer women and 75 women with benign breast mass as a control group were included in the study. The control and the patient groups were aged matched. The age range of the control group was between 25 to 70 years (mean ± SD: 50.4 ± 15.1 years). The age range of the patient group was between 25 to 71 yeas (mean ± SD: 49.1 ± 14.6 years). The patients were undergone radical modified mastectomy, then treated with chemotherapy and radiotherapy after the operation. Five mL of blood samples from the patient and control groups were taken, and the patient samples were taken before the operation. The blood samples were analyzed for serum lipid profile. The patients and the control groups were advised to fast for 14 hours before taking the blood samples. Body mass index was measured for the patients and controls. The stage, lymph involvement, and metastasis of the cancer were also included.Results: Body mass index (BMI) in patients was significantly higher than controls. However, serum total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and atherogenic index (AI), in the patients were significantly lower than controls. High-density lipoprotein cholesterol (HLD-C) was higher in the patients compared with the controls but not significant.Conclusion: a significant decrease in TC, TGs, and LDL-C with no significant increase for HDL-C was noticed in breast cancer women. Serum lipid profile may not be considered as a risk factor for breast cancer.

Potential of dried bread enriched with red palm oil to improve lipid profile, and control oxidative stress: An experimental study in adult men with dyslipidaemia

Dyslipidaemia is an abnormality of lipid metabolism, characterised by the increased levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and decreased levels of high-density lipoprotein cholesterol (HDL-C), which cause antioxidant enzymes to decrease, and trigger oxidative stress, characterised by an increase in lipid peroxidation. The present work examined the effect of consumption of dried breads enriched with red palm oil (RPO) to improve serum lipid profiles, and control oxidative stress in adult men with dyslipidaemia. This randomised double-blind controlled trial involved adult men with an abnormal lipid profile, and had a body mass index between 18.5 and 26.9 kg/m2. Each subject consumed two pieces of dried bread per packet as a snack for eight weeks. Subjects were randomly assigned into two groups: those who consumed dried breads with RPO (experiment), and those who consumed dried breads without RPO (control). Serum levels of lipid profile parameters (total cholesterol, triglyceride, LDL-C, HDL-C) and control oxidative stress markers [superoxide dismutase (SOD) enzyme, malondialdehyde (MDA), oxidised LDL (oxLDL), and β-carotene serum] were measured before and after the intervention. In subjects who consumed dried breads with RPO, there was a significant decrease in total cholesterol and LDL-C levels (p = 0.020 and 0.041, respectively); whereas serum triglyceride and HDL-C levels were not significantly affected (p = 0.083 and 0.233, respectively). Further, the consumption of dried breads with RPO significantly (p = 0.018) increased SOD activity which led to a significant decrease in MDA and oxLDL levels (p = 0.036 and 0.047, respectively), but non-significant on the increase in β-carotene serum levels (p = 0.166). Therefore, daily consumption of 60 g dried breads with RPO has the potential to be a functional food that can be used as a snack that efficiently lowers total and LDL cholesterol levels in adult men with dyslipidaemia, but without deleterious effects on biomarkers of oxidative stress.

Exergaming During Ramadan Intermittent Fasting Improve Body Composition as Well as Physiological and Psychological Responses to Physical Exercise in Adolescents With Obesity.

The effects of exergaming on biochemical responses has been investigated; however, no data is available for this effect during Ramadan intermittent fasting (RIF). RIF is a daily fasting characterized by abstaining from eating and drinking from sunrise to sunset for 29–30 days. The purpose of this study was to investigate the effect of exergaming during RIF on body composition, physical performance and hematological parameters in overweight and adolescents with obesity. Twenty-four adolescents with obesity were divided into two groups [control group (CG), n = 12, or cooperative sport exergaming group (EG), n = 12: 45 min per session during five days per week)]. Participants completed a 6-min walking test (6MWT), a squat jump test and a 10 and a 30m sprint tests in four different occasions: before Ramadan (T0), the second week of Ramadan (T1), the fourth week of Ramadan (T2), and after Ramadan (T3). Blood pressure, rating of perceived exertion (RPE), body composition, central obesity index, dietary intake and profile of mood states (POMS) were, also, assessed over the four periods. The results showed that body weight, body mass index and body fat percentage were significantly lower at T2 compared to T0 and T1 in the EG. After RIF, body composition returned to the values recorded before RIF. The POMS score was significantly lower during T2 compared to T0, T1 and T3 in the EG. The vertical jump and the 6MWT distance were significantly higher (i) at T2 compared to T0, T1 and T3 in the EG and (ii) in EG compared to CG at T2. RPE was significantly lower (i) at T2 compared to T0, T1 and T3 in the EG and (ii) in EG compared to CG at T2. Blood pressure was lower during T2 compared to the other periods in EG. The EG experienced significant decreases in total cholesterol and triglycerides during T2. However, no significant changes between groups and periods was reported for all the other parameters. In conclusion, exergaming during RIF has a positive effect on body composition and physiological and psychological responses in adolescents with obesity.

Dandelion (Taraxacum officinale) seeds extract attenuates hypercholesterolemia in swiss albino mice

ObjectivesThe present search aimed to investigate the effect of dandelion seeds extract to reduce hypercholesterolemia and its hazardous effects on liver. MethodsForty male albino mice were divided into 4 groups, 10 mice per each, the first was the untreated control, the second treated with 400 mg/kg dandelion seed extract, the third treated with 5 mg/kg of cholesterol powder dissolved in oil and the fourth treated with cholesterol and dandelion extract. ResultsIt was showed that dandelion seeds extract reduced the weight of the mice. Cholesterol treatment resulted in highly significant increase of liver enzymes activities, total cholesterol, how-density lipoprotein (HDL) and low-density lipoprotein (LDL) of serum besides to pathological changes as steatosis, inflammation, fibrosis and high pathological score in the liver. Dandelion seeds extraction treatment resulted in marked decrease of liver enzymes activities total cholesterol, HDL and LDL of serum, in addition to hepatic tissue improvement with less steatosis, inflammation, fibrosis and lowered pathological score. ConclusionDandelion seeds extract could reduce hypercholesterolemia in swiss albino mice.

Long Term Whole Egg, but Not Egg White Supplementation Promotes Growth and Bifidobacteria and Lachnospira Without Increasing LDL-Cholesterol in Primary School Children

ObjectivesWe aimed to determine long-term effects of egg supplementation on growth, blood lipoproteins, blood proteins, nutritional status, and microbiota in primary school children.MethodsA randomized controlled, cluster study was performed at 6 rural schools in Central, Eastern, and Western Thailand. 635 students (8–14 years old) were recruited into the study. Subjects were randomly assigned into 3 groups, based on weight for age: 1) Whole eggs (WE) - consume 10 additional eggs per week [n = 238] 2) Egg substitute (ES) - consume yolk-free egg substitute equivalent to 10 eggs per week [n = 200], and 3) control group (C, [n = 197]). The anthropometric, biochemical indexes, dietary intake, and microbiota were measured at week 0 (baseline), week 13–14, and week 34–35.ResultsAt baseline, 14% were under-weighed, 9% were stunted, and 16% were wasted. At 34–35 weeks, the increases in body weight and height were higher in WE group than those in C group (3.56 ± 0.93 kg, P < 0.001 and 5.11 ± 0.92 cm, P < 0.001). No significant differences in weight and height were observed between the ES and C groups. Prealbumin levels were higher (1.53 ± 0.33 mg/dL, P < 0.001) in WE but not ES as compared with C. There were significant decreases in total cholesterol, triglycerides, and LDL cholesterol in WE but not ES as compared with C. Additionally, HDL cholesterol tended to increase in WE (0.66 ± 0.99 mg/dL, ns) as compared with C. Bacterial diversity in WE, ES and C group was not significantly change neither alpha nor beta diversity. After whole egg supplementation, the overall relative abundance of the Bifidobacterium was increased up to 1.28-fold. The differential abundance analysis also indicated that Lachnospira significantly increased and Varibaculum significantly decreased after whole egg supplementation.ConclusionsLong-term whole egg supplementation significantly enhanced growth in young children with no adverse effect on blood cholesterol levels. The result coincided with promoting health-benefit gut bacteria. However, further insight into the mechanistic effect of egg consumption on gut microbiota and growth is needed.Funding SourcesAgricultural Research Development Agency (ARDA), Thailand.

Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction.

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been shown to significantly reduce cardiovascular mortality, heart failure hospitalizations, and all-cause mortality in patients with heart failure with reduced ejection fraction. This study aims to investigate the long-term impact of the sacubitril/valsartan combination on lipid parameters in patients with heart failure with reduced ejection fraction. For this single-center retrospective cross-sectional study, data of patients using sacubitril/valsartan because of heart failure with reduced ejection fraction were collected. In addition to routine controls, the patients' lipid levels were measured at 3-month intervals. The parameters that were obtained over 3 years included total cholesterol, high-density lipoprotein cholesterol, triglyceride, and N-terminal pro-B-type natriuretic peptide levels. A total of 192 patients with a functional capacity New York Heart Association II-V, and who were using sacubitril/valsartan because of heart failure with reduced ejection fraction, were included in this study. Independent of statin use, there was a decrease in total cholesterol levels (196.1 ± 44.8 mg/dL vs 161.5 ± 41.7 mg/dL, p < 0.001) and triglyceride levels (159.1 ± 10.4 mg/dL vs 121.4 ± 6.9 mg/dL, p < 0.001), and there was an improvement in high-density lipoprotein cholesterol levels (44.9 ± 1.9 mg/dL vs 48.2 ± 2.4 mg/dL, p < 0.001) when comparing baseline levels with third-year levels. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction, independent of statin use, may cause a decrease in total cholesterol and triglyceride levels and an improvement in high-density lipoprotein cholesterol levels.

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications.

Non-alcoholic fatty liver disease (NAFLD) is the most widespread liver disease, characterized by fatty acids liver accumulation and subsequent fibrosis. NAFLD prevalence ranges from 80% to 90% in obese subjects and is estimated to be around 50% in patients with metabolic syndrome. In this clinical scenario, diet and lifestyle modifications can play an important role. There are several imaging techniques that can accurately diagnose fatty liver. Recently, ultrasound has acquired a leading role in the diagnosis and follow-up of fatty liver disease. Furthermore, elastosonography represents a valid alternative to liver biopsy. Shear wave elastosonography evaluates the elastic and mechanical properties of liver tissue. The aim is to evaluate the effects of lifestyle and nutritional interventions and a loss of body weight during hepatic steatosis through ultrasonographic and elastosonographic techniques. Thirty-two female subjects with metabolic syndrome were subjected to clinical, anthropometric, and laboratory assessments, as well as abdominal ultrasonographic/elastosonographic measurements taken from enrollment time (T0) and after 3 months (T1) of lifestyle modifications. After 3 months of lifestyle changes, significant weight loss was observed, with a marked improvement in all adiposity indices. The laboratory parameters at T1 showed significant decreases in total and LDL cholesterol, triglycerides, basal blood glucose, 120 min glycaemia, basal insulin and HOMA Index (p < 0.001). A similar improvement was observed at T1 for steatosis degree (p < 0.01) and elastosonographic measurements (Kpa p < 0.001). The linear regression analysis of the baseline conditions documented that the size of the liver positively correlated with body weight, BMI, neck and waist circumferences, waist to height ratio (WhtR), insulin and HOMA Index, fat mass and visceral fat, and steatosis grade. After 3 months, the liver size showed improvement with positive correlations to all previous variables. Hepatic stiffness (Kpa) positively correlated with neck circumference, visceral fat, and ALT, with basal insulin, gamma-GT, and AST, and with waist circumference, WhtR, and fat mass. The degree of steatosis was positively correlated with more variables and with greater statistical significance at T1 with respect to T0. Particularly, the positive correlations between the degree of steatosis and neck circumference (p < 0.001), HOMA Index, and triglycerides (p < 0.001) appeared to be very significant. NAFLD management in women with metabolic syndrome should be focused on lifestyle modifications. Moreover, liver involvement and improvement at follow-up could be evaluated in a non-invasive manner through ultrasonographic and elastosonographic techniques.

Synergistic Hypolipidemic and Immunomodulatory Activity of Lactobacillus and Spirulina platensis

Hyperlipidemia is a significant risk factor for atherosclerosis and coronary heart disease (CHD). The aim of this study was to investigate hypolipidemic effects of Lactobacillus, Spirulina and their combination on Swiss albino mice fed a regular or high-cholesterol diet. Rosuvastatin was used as a reference drug The highest body weight, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol LDL-C and the lowest high-density lipoprotein cholesterol were recorded in a positive control group (G5). Treatment with Lactobacillus or Spirulina or by their combination resulted in a significant decrease in body weight, TC, TG, LDL-C and significant increase in HDL-C (p &lt; 0.05) in both mice fed a regular diet or high-cholesterol diet. The treatments induced a significant increase in Hb, MCHC and HCT levels in mice fed a regular diet (p &lt; 0.05). They did not induce a significant effect on these parameters in mice fed a high-cholesterol diet, while treatment with standard rosuvastatin induced a significant decrease in these parameters (p &lt; 0.05). The treatments induced a significant increase in the platelet count and WBC number in mice fed a regular diet p &lt; 0.05), while they induced significant decrease in these parameters in mice fed a high-cholesterol diet p &lt; 0.05. They also stimulated the innate immunity represented by both monocyte and neutrophil cells in mice fed a regular diet, while this immunity was reduced in mice fed a high-cholesterol diet. It also caused a marked reduction in inflammation and an improvement in the congestion of cardiac tissues, the aorta, and the spleen. The treatment of hyperlipidemic mice with combination of Lactobacillus and Spirulina gave similar results to those obtained with treatment by rosuvastatin.

The role of ω3-polyunsaturated fatty acids in the prevention of atherogenic cardiovascular diseases starting in childhood

Diseases of the cardiovascular system are one of the main causes of morbidity, disability and mortality. One of the most significant risk factors for their development is atherogenic dyslipidemia. Atherosclerotic vascular damage occurs long before clinical manifestation and often begins to progress as early as childhood. This is why children represent the most important cohort for the prevention of cardiovascular diseases of atherosclerotic genesis. Studies show that taking ₃-polyunsaturated fatty acids reduces the risk of atherosclerotic vascular disease in adults and children. The effect is achieved by multidirectional effects on risk factors such as insulin resistance, obesity, diabetes mellitus, dyslipidaemia, arterial hypertension, inflammation and endothelial dysfunction. In children with primary dyslipidemia (heterozygous familial hypercholesterolemia) taking ₃-polyunsaturated fatty acids leads to normalization of serum triglycerides and a moderate decrease in total cholesterol and low-density lipoprotein cholesterol. The most significant therapeutic and prophylactic effects are observed in patients with secondary dyslipidemias caused by obesity and diabetes mellitus, when, besides the decrease in triglycerides and the increase in HDL cholesterol, ₃-polyunsaturated fatty acids increase the insulin sensitivity of cells and tissue, body weight reduction, increase in muscle mass, stabilization of blood pressure and improvement of liver function are observed. Considering pleiotropic protective effect and good tolerability, ₃-polyunsaturated fatty acids can be widely used for primary and secondary prevention of atherosclerotic cardiovascular diseases in children and adolescents.

Effects of an Iranian traditional fermented food consumption on blood glucose, blood pressure, and lipid profile in type 2 diabetes: a randomized controlled clinical trial.

Ash-Kardeh is one of the few fermented foods without a dairy base in Iran, which is traditionally prepared from cereals and plants in the presence of microorganisms (mainly lactic acid bacteria). This study aimed to assess the effects of Ash-Kardeh consumption on blood glucose, lipid profile, and blood pressure in type 2 diabetic patients. Forty-six patients with type 2 diabetes were studied in this randomized controlled clinical trial. Subjects were randomly allocated into intervention (n = 23) and control (n = 23) groups. Individuals of both groups received the usual treatment of diabetic patients, while those in the intervention group, in addition to the usual treatment, received 250g of Ash-Kardeh daily for 6 weeks. Fasting blood glucose, blood pressure, and lipid profiles were measured before and after the intervention. Compared to the control group, Ash-Kardeh consumption led to a significant decrease in fasting blood glucose (P = 0.003), total cholesterol (P = 0.025), triglyceride (P = 0.003), systolic (P < 0.001), and diastolic blood pressure (P = 0.014) in the intervention group. Also, a significant increase in the concentrations of high-density lipoprotein cholesterol (P = 0.048) was observed after Ash-Kardeh consumption. It seems that Ash-Kardeh consumption could improve high blood glucose, lipid profile, and hypertension in type 2 diabetic patients but does not affect low-density lipoprotein cholesterol concentrations. This study was registered on 2019-09-15 in the Iranian Registry of Clinical Trials ( www.irct.ir ) with the code number IRCT20170202032367N3.

MO244: PCSK9 Inhibitors are Efficient in Treatment of Resistant Hypercholesterolemia in Nephrotic Syndrome

Abstract BACKGROUND AND AIMS Hypercholesterolemia in nephrotic syndrome is commonly resistant to statin therapy and represents an important clinical challenge both for cardiovascular risk prevention and to eliminate lipotoxic effect on podocytes. Serum PCSK9 level is elevated in nephrotic syndrome and has a key pathophysiologic role in development and persistance of hyperlipidemia. Thus, we aimed to investigate the role of PCSK9 inhibitors in control of hypercholesterolemia in patients with neprotic syndrome. METHOD Consecutive patients with nephrotic syndrome and elevated atherogenic Lp (a) (n = 4) and patients with resistant secondary glomerulonephritis with nephrotic proteinuria (n = 2) were included. In all patients, in addition to full dose statin therapy, evolocumab 420 mg s.c. monthly was introduced. Lipid levels were measured after a median of 4 (range 2–9) months after starting evolocumab. RESULTS Nephrotic syndrome was caused by focal segmental glomerulosclerosis in four patients (66.7%) and membranous nepropathy was the cause in two patients (33.3%). Median age of included patients was 49.5 (range 24–70) years. Four patients with primary cause of glomerulonephritis received specific imunosupressive treatment. During follow-up, we observed descrease in glomerular filtration rate (eGFR median 58.5 interquartile range (IQR) [46.7–98.7] mL/min/1.73 m2 versus median 47 IQR [38.25–89.25] mL/min/1.73 m2; P = .046) and persistence of proteinuria [median 11 970 IQR (3862–13 765) mg/dU versus median 10 847 (5407–14 340) mg/dU; P = .753]. However, despite persistent proteinuria and decrease in eGFR, significant decrease in total cholesterol [median 9.10 IQR (6.92–10.87) mmol/L versus median 6.81 (5.4–8.45) mmol/L; P = .028] and LDL cholesterol [median 5.40 IQR (4.12–7.25) versus median 4.04 IQR (2.70–4.60); P = .046] was observed. There was no significant difference in Lp (a) and triglyceride levels. CONCLUSION PCSK9 inhibitors are a promising new therapeutic option for hyperlipidemia in patients with nephrotic syndrome. Further research, including a larger number of patients, is needed to correctly position PCSK9 inhibitors in treatment of hyperlipidemia in patients with nephrotic syndrome.

MO797: Roxadustat Decreases Serum Lipids Levels in Hemodialysis Patients

Abstract BACKGROUND AND AIMS The activity of hypoxia-inducible factor (HIF), an oxygen-sensitive transcription factor involved in erythropoiesis, is regulated by HIF-prolyl hydroxylases. With decreased oxygen tension, the activity of these enzymes is suppressed, resulting in increased erythropoiesis [1]. Roxadustat is an oral HIF-prolyl hydroxylase inhibitor (HIF-PHI) developed for dialysis-dependent chronic kidney disease (CKD) anemia. While the impact of HIF-PHI on mean hemoglobin (Hb) change in patients on hemodialysis (HD) has already been investigated [2], its effects on serum lipid levels have yet to be explored. Clarifying such effects is particularly important because chronic HD patients usually have lower plasma high-density lipoprotein (HDL)-cholesterol (C) levels than healthy subjects. The aim of this study is to investigate the effects of roxadustat on serum lipid levels in HD patients. METHOD Study 1: This multicenter observational cohort study investigated the demographic and clinical information of 258 patients on HD (73 women and 185 men) who were being treated for anemia by HIF-PHI between 1 February 2020 and 31 May 2021, at Zenjinkai Group dialysis centers in Japan. Study 2: This study evaluated the efficacy of roxadustat in 24 patients (3 women and 21 men) for HD-dependent CKD anemia and dyslipidemia &amp;gt;24 weeks. RESULTS Study 1: The mean age and HD periods were 71.2 ± 12.2 and 5.5 ± 6.6 years, respectively. The patient's CKDs were diabetic nephropathy (n = 72; 27.9%), chronic glomerular nephritis (CGN) (n = 36; 14%), nephrosclerosis (n = 32; 12.4%) and other pathologies (n = 118; 45.7%). HIF-PH inhibitors used for patients on HD were roxadustat (n = 105), daprodustat (n = 117), vadadustat (n = 14) and enadustat (n = 22). Study 2: The mean age and HD periods were 76.5 ± 7.7 and 5.3 ± 3.9 years, respectively. The patient's CKDs were CGN (n = 6; 25%), nephrosclerosis (n = 6; 25%), diabetic nephropathy (n = 4; 16.7%), unknown pathologies (n = 4; 16.7%) and others (n = 4; 16.7%). Roxadustat treatment did not lead to a significant change in mean Hb values (from 10.4 ± 0.8 to 10.5 ± 0.9 g/dL). There were no significant changes in mean triglycerides (TG), transferrin saturation (TSAT) or ferritin. However, there was a statistically significant decrease (P &amp;lt; .001) in mean total cholesterol (TC) (from 144.0 ± 35.6 to 121.3 ± 38.5 mg/dL), low-density lipoprotein (LDL)-C (from 79.8 ± 26.6 to 62.8 ± 26.2 mg/dL) and HDL-C (from 45.0 ± 12.6 to 38.4 ± 11.9 mg/dL). Furthermore, there were also significant increases in mean serum iron (from 68.1 ± 17.4 to 81.8 ± 31.1 μg/dL; P = .01) and the mean total iron-binding capacity (TIBC) (from 220.0 ± 46.7 to 265.1 ± 54.7 μg/dL; P &amp;lt; .001). Case report: A 56-year-old woman who had undergone HD for 13 years due to CKD due to diabetic nephropathy was hospitalized with cerebral infraction, peripheral arterial disease, heart failure and ischemic heart disease. The patient was treated with percutaneous coronary intervention (PCI) and started on 100 mg of roxadustat 3 times a week. After roxadustat treatment, the following parameters increased: Hb (from 10.7 to 10.8 g/dL), ferritin (from 74 to 103 ng/mL) and TIBC (from 204 to 223 μg/dL). On the other hand, the following parameters decreased: TC (from 325 to 125 mg/dL), TG (from 318 to 165 mg/dL), HDL-C (from 41 to 33 mg/dL) and LDL-C (from 227 to 55 mg/dL). The patient was discharged from the hospital after 3 months. CONCLUSION Roxadustat treatment improves iron metabolism, keeps Hb levels stable and significantly decreases mean LDL-C and HDL-C. Therefore, this drug may have useful effects on dyslipidemia in patients on HD.